Matthew Weston
Stock Analyst at UBS
(4.70)
# 884
Out of 5,116 analysts
357
Total ratings
78.6%
Success rate
13.7%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €62.00 → €66.00 | €55.58 | +18.75% | 26 | Nov 4, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €150.00 | €148.75 | +0.84% | 40 | Nov 4, 2026 | |
| SWX: RO Roche Holding AG | Downgraded: Hold | CHF 440.00 | CHF 400.00 | +10.00% | 1 | Nov 2, 2026 | |
| SWX: ROP Roche Holding AG | Downgraded: Hold | CHF 376.00 → CHF 420.00 | CHF 390.30 | +7.61% | 58 | Nov 2, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 1,940p | 1,890p | +2.65% | 21 | Oct 29, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 116.00 → CHF 130.00 | CHF 133.08 | -2.31% | 52 | Oct 28, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €300.00 | €290.00 | +3.45% | 32 | Oct 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €260.00 | €225.80 | +15.15% | 18 | Oct 15, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €78.00 | €83.74 | -6.85% | 18 | Oct 15, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 200.00 | CHF 191.75 | +4.30% | 13 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 17,600p | 13,930p | +26.35% | 68 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $146.73 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 750.00 | CHF 663.40 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | €158.70 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $310 | $40.31 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $162.55 | n/a | 1 | Jul 5, 2017 |
Bayer Aktiengesellschaft
Nov 4, 2026
Reiterated: Buy
Price Target: €62.00 → €66.00
Current: €55.58
Upside: +18.75%
Merck KGaA
Nov 4, 2026
Reiterated: Hold
Price Target: €150.00
Current: €148.75
Upside: +0.84%
Roche Holding AG
Nov 2, 2026
Downgraded: Hold
Price Target: CHF 440.00
Current: CHF 400.00
Upside: +10.00%
Roche Holding AG
Nov 2, 2026
Downgraded: Hold
Price Target: CHF 376.00 → CHF 420.00
Current: CHF 390.30
Upside: +7.61%
GSK plc
Oct 29, 2026
Reiterated: Hold
Price Target: 1,940p
Current: 1,890p
Upside: +2.65%
Novartis AG
Oct 28, 2026
Reiterated: Hold
Price Target: CHF 116.00 → CHF 130.00
Current: CHF 133.08
Upside: -2.31%
Sartorius Aktiengesellschaft
Oct 23, 2026
Reiterated: Buy
Price Target: €300.00
Current: €290.00
Upside: +3.45%
Sartorius Stedim Biotech S.A.
Oct 15, 2026
Reiterated: Buy
Price Target: €260.00
Current: €225.80
Upside: +15.15%
Sanofi
Oct 15, 2026
Reiterated: Hold
Price Target: €78.00
Current: €83.74
Upside: -6.85%
Galderma Group AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 200.00
Current: CHF 191.75
Upside: +4.30%
Aug 4, 2026
Reiterated: Buy
Price Target: 17,600p
Current: 13,930p
Upside: +26.35%
Nov 1, 2024
Reiterated: Buy
Price Target: $125
Current: $146.73
Upside: n/a
Jan 27, 2022
Reiterated: Buy
Price Target: CHF 750.00
Current: CHF 663.40
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: €158.70
Upside: n/a
Nov 2, 2018
Reiterated: Hold
Price Target: $310
Current: $40.31
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $162.55
Upside: n/a